Objectives: Human amniotic epithelial cells have multipotent differentiation capacity and are considered as potential therapeutic cells for clinical use. This study represents the first published report on the evaluation of the safety and clinical feasibility of human amniotic epithelial cells for transplant into knee joints, serving as an initial step for subsequent therapeutic evaluations within arthritis clinics.
Materials and methods: Our experimental design was based on subjecting groups of rabbits as a recipient model for human amniotic epithelial cell transplant into knee joints. Twenty rabbits received 200 μL sterile 0.9% sodium chloride solution containing 1 × 10⁹ human amniotic epithelial cells/knee joint by intra-articular injection. Control groups received cell-free saline into knees, and some animals were not treated. After 10 days of xenotransplant, radiology scans and histologic sections of transplanted and nontrans planted knees were examined and compared. Immunohistochemistry staining was also applied to detect tumor necrosis factor-alpha and interleukin 17 (as inflammatory and immuno-rejection markers) in knee sections.
Results: Similar to results shown in noninjected and saline-injected knees, all treated knees appeared normal, with no signs of acute immunorejection, no microbial colonization, no pain, no allergic reactions, no inflammation, and normal motion. Use of human amniotic epithelial cells appeared safe without risk of immunorejection or tumor formation in the transplanted knee joint.
Conclusions: Human amniotic epithelial cells can be safely transplanted into knee joints, encouraging a need for complementary research for further therapeutic evaluations of human amniotic epithelial cells for curing arthritis.